M
9.96
0.51 (5.40%)
| Previous Close | 9.45 |
| Open | 9.45 |
| Volume | 168,306 |
| Avg. Volume (3M) | 786,646 |
| Market Cap | 956,588,224 |
| Price / Earnings (TTM) | 11.45 |
| Price / Earnings (Forward) | 64.10 |
| Price / Sales | 2.50 |
| Price / Book | 5.23 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2026 |
| Operating Margin (TTM) | -2,159.71% |
| Diluted EPS (TTM) | -2.31 |
| Quarterly Revenue Growth (YOY) | 176.30% |
| Total Debt/Equity (MRQ) | 244.35% |
| Current Ratio (MRQ) | 1.52 |
| Operating Cash Flow (TTM) | -104.58 M |
| Levered Free Cash Flow (TTM) | -53.25 M |
| Return on Assets (TTM) | -37.28% |
| Return on Equity (TTM) | -216.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | MeiraGTx Holdings plc | Mixed | Bearish |
AIStockmoo Score
-0.8
| Analyst Consensus | NA |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | -2.5 |
| AI Insight | NA |
| Weighted Average | -0.83 |
Select this tab to load the latest available analysis.
|
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 24.27% |
| % Held by Institutions | 60.04% |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |